Organon

OGN

Jersey City, United States· Est. 2021

organon.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

OGN · Stock Price

USD 13.32+4.61 (+52.93%)

Market Cap: $3.5B

Historical price data

Market Cap: $3.5BPipeline: 200 drugs (155 Phase 3)Founded: 2021Employees: ~9,500HQ: Jersey City, United States

Sector Ranking#82 in Biologics / Biosimilars

Overview

Organon's mission is to improve the health of women throughout their lives by addressing critical gaps in reproductive health, contraception, fertility, and menopause. The company has achieved immediate global scale with a portfolio in over 140 markets, leveraging its heritage brands and deep commercial expertise. Its strategy focuses on maximizing the value of its established therapeutic portfolio, expanding access to biosimilars, and advancing a targeted pipeline in women's health to drive sustainable growth.

Women's HealthBiosimilarsEstablished Brands (Cardiovascular, Respiratory, Dermatology, CNS, etc.)

Technology Platform

A commercialization and lifecycle management engine for established pharmaceuticals, coupled with a focused business development and partnership model for biosimilars and late-stage women's health innovations.

Pipeline

200

200 drugs in pipeline155 in Phase 3

Drug	Indication	Stage
Asenapine + Placebo	Schizophrenia	Phase 3
NOMAC-E2 + LNG-EE	Contraception	Phase 3
MK0653, ezetimibe + Comparator: fenofibrate monotherapy	Hypercholesterolemia	Phase 3
Corifollitropin alfa + FSH + GnRH antagonist + (rec)hCG + Pr...	In Vitro Fertilization	Phase 3
mometasone furoate dry powder inhaler + Budesonide DPI	Asthma	Phase 3

Funding History

IPOUndisclosedUndisclosedJun 3, 2021

FDA Approved Drugs

BILDYOSBLAAug 29, 2025

BILPREVDABLAAug 29, 2025

VTAMANDAMay 23, 2022

Opportunities

Organon has significant opportunities to expand global access to its women's health portfolio in emerging markets, drive growth through its recently acquired assets (Phexxi, Orilissa), and capture market share in the rapidly growing biosimilars segment through its partnership with Samsung Bioepis.

The increasing focus and investment in women's health globally provides a favorable tailwind.

Risk Factors

Key risks include a high debt burden limiting flexibility, ongoing revenue erosion from generic competition to established brands, execution risks in integrating new acquisitions and launching pipeline products, and intense pricing pressure in the biosimilars market.

Competitive Landscape

Organon competes in women's health against large pharma (Bayer, Pfizer) and biotechs, in biosimilars against giants like Sandoz and Amgen, and defends its established brands against generic manufacturers. Its competitive edge lies in its focused strategy, global commercial scale, and deep expertise in lifecycle management.